First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

Background. The purpose of this nonrandomized, open‐label, phase I study ({"type":"clinical-trial","attrs":{"text":"NCT01285037","term_id":"NCT01285037"}}NCT01285037) was to evaluate the safety and tolerability of merestinib, an oral antiproliferative and antiangiogenic kinase inhibitor, and to determine a recommended phase II dose and schedule for patients with advanced cancer.